Afficher la couverture 'Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses | Brier, Lucile' en grand format
/5

0 avis

Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses

Archive ouverte

Brier, Lucile | Hassan, Haitham | Hanoulle, Xavier | Landry, Valerie | Moschidi, Danai | Desmarets, Lowiese | Rouillé, Yves | Dumont, Julie | Herledan, Adrien | Warenghem, Sandrine | Piveteau, Catherine | Carré, Paul | Ikherbane, Sarah | Cantrelle, François-Xavier | Dupré, Elian | Dubuisson, Jean | Belouzard, Sandrine | Leroux, Florence | Deprez, Benoit | Charton, Julie

Edité par CCSD ; Elsevier -

International audience. Since end of 2019, the global and unprecedented outbreak caused by the coronavirus SARS-CoV-2 led to dramatic numbers of infections and deaths worldwide. SARS-CoV-2 produces two large viral polyproteins which are cleaved by two cysteine proteases encoded by the virus, the 3CL protease (3CLpro) and the papain-like protease, to generate non-structural proteins essential for the virus life cycle. Both proteases are recognized as promising drug targets for the development of anti-coronavirus chemotherapy. Aiming at identifying broad spectrum agents for the treatment of COVID-19 but also to fight emergent coronaviruses, we focused on 3CLpro that is well conserved within this viral family. Here we present a high-throughput screening of more than 89,000 small molecules that led to the identification of a new chemotype, potent inhibitor of the SARS-CoV-2 3CLpro. The mechanism of inhibition, the interaction with the protease using NMR and X-Ray, the specificity against host cysteine proteases and promising antiviral properties in cells are reported.

Suggestions

Du même auteur

NMR spectroscopy of the main protease of SARS‐CoV‐2 and fragment‐based screening identify three protein hotspots and an antiviral fragment

Archive ouverte | Cantrelle, François-Xavier | CCSD

International audience. The main protease (3CLp) of the SARS-CoV-2, the causative agent for the COVID-19 pandemic, is one of the main targets for drug development. To be active, 3CLp relies on a complex interplay be...

Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice

Archive ouverte | Belouzard, Sandrine | CCSD

International audience. Drug repurposing has the advantage of shortening regulatory preclinical development steps. Here, we screened a library of drug compounds, already registered in one or several geographical are...

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology

Archive ouverte | Belouzard, Sandrine | CCSD

The fastest way to implement a treatment against a new rapidly emerging viral disease consists in screening the potential antiviral activity of drugs approved for human use. This has the advantage of shortening regulatory preclini...

Chargement des enrichissements...